U.S. markets open in 9 hours 21 minutes

Invacare Corporation (IVC)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
0.8737+0.0022 (+0.25%)
At close: 04:00PM EDT
0.9200 +0.05 (+5.30%)
After hours: 04:46PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.8715
Bid0.8370 x 1300
Ask0.9200 x 1100
Day's Range0.8249 - 0.9200
52 Week Range0.8000 - 5.3600
Avg. Volume387,673
Market Cap33.472M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-1.5920
Earnings DateOct 25, 2022 - Oct 31, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 02, 2020
1y Target Est3.27
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IVC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Invacare Corporation
    IVC: What does Argus have to say about IVC?INVACARE CORP has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    11 months agoArgus Research
View more
  • American City Business Journals

    Invacare ousts CEO after agreeing to cooperate with largest shareholder

    Elyria, Ohio, medical equipment maker Invacare Corp. has ousted its chairman, president and CEO less than a week after agreeing to cooperate with its largest shareholder. Gone is Matthew Monaghan, who was hired in 2015 to help steady Invacare, then reeling from a big cut in federal reimbursements for its durable medical equipment and an FDA consent decree related to its wheelchair manufacturing, according to SmartBusiness. On Sunday, Invacare promoted Geoffrey Purtill, its senior vice president and general manager, as interim president and chief executive, the company said in a statement.

  • Business Wire

    Invacare Corporation Announces Executive Leadership Changes

    ELYRIA, Ohio, August 29, 2022--Invacare Corporation (NYSE: IVC) today announced changes to its senior management team and Board of Directors to advance its previously announced business transformation initiatives, address supply chain challenges, and strengthen its financial performance. Geoffrey P. Purtill, who had been serving as the company’s Senior Vice President and General Manager, EMEA and APAC, was named interim President and Chief Executive Officer, replacing Matthew E. Monaghan, who ha

  • Business Wire

    Invacare Corporation Announces Cooperation Agreement With Azurite Management

    ELYRIA, Ohio, August 22, 2022--Invacare Corporation (NYSE: IVC) today announced that it has entered into a cooperation agreement with its largest shareholder, Azurite Management LLC ("Azurite"), which currently owns approximately 10.3% of the company’s outstanding shares as of June 30, 2022. As part of the agreement, Invacare appointed two new independent directors, Steven H. Rosen and Ambassador Edward F. Crawford, effective immediately. Mr. Rosen will serve on the company’s Audit and Compensat